Database : MEDLINE
Search on : thyroiditis [Words]
References found : 16515 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1652 go to page                         

  1 / 16515 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29481981
[Au] Autor:Qin J; Li L; Jin Q; Guo D; Liu M; Fan C; Li J; Shan Z; Teng W
[Ad] Address:Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, Shenyang 110001, PR China.
[Ti] Title:Estrogen receptor ß activation stimulates the development of experimental autoimmune thyroiditis through up-regulation of Th17-type responses.
[So] Source:Clin Immunol;, 2018 Feb 23.
[Is] ISSN:1521-7035
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Estrogens play important roles in autoimmune thyroiditis, but it remains unknown which estrogen receptor (ER) subtype mediates the stimulatory effects. Herein we treated ovariectomized mice with ERα or ERß selective agonist followed by thyroglobulin-immunization to induce experimental autoimmune thyroiditis (EAT), and observed the aggravation of EAT after diarylpropionitrile (DPN, ERß selective agonist) administration. The mRNA levels of interleukin(IL)-17A, IL-21 and RORγt and percentages of T helper (Th) 17 cells were up-regulated in the splenocytes of DPN-treated mice. Activated ERß was found directly binding to IL-17A and IL-21 gene promoters, and also indirectly promoting IL-21 and RORγt gene transcription through interaction with NF-κB. The expressions of co-stimulatory molecules were increased on antigen-presenting cells (APCs) after DPN administration. It suggests that ERß is the predominant ER subtype responsible for EAT development, and its activation may enhance Th17-type responses through genomic pathways and alteration of APCs' activities.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 16515 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29505532
[Au] Autor:Li J; Li J; Jiang S; Yu R; Yu Y
[Ad] Address:Department of Endocrinology and Metabolism.
[Ti] Title:Case report of a pituitary thyrotropin-secreting macroadenoma with Hashimoto thyroiditis and infertility.
[So] Source:Medicine (Baltimore);97(1):e9546, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Thyrotropin-secreting adenoma (TSHoma) is rare, diagnosis and treatment are often delayed if the condition coexists with Hashimoto thyroiditis. The enlarged pituitary adenoma may eventually induce panhypopituitarism, infertility, or the compression of optic nerves and optic chiasma. PATIENT CONCERNS: This patient was a 36-year-old man who had been referred to the pituitary disease multidisciplinary team (MDT) of the West China Hospital, due to infertility. DIAGNOSES: Examinations revealed pituitary thyrotropin-secreting macroadenoma. INTERVENTIONS: We conducted trans-sphenoidal surgery. Human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) were used for reproductive reconstruction after surgery. OUTCOMES: This patient successfully fathered a child. LESSONS: To date, the multidisciplinary team treatment of TSHoma was rare, TSHomas are often misdiagnosed as macroadenomas, because the clinical features are varied and it often takes a long time to be diagnosed. So the purpose of this case report is to attract attention to the manifestation of increased thyroid stimulating hormone (TSH) concentration and discuss MDT treatment for TSH-secreting adenoma.
[Mh] MeSH terms primary: Adenoma/complications
Hashimoto Disease/complications
Infertility, Male/etiology
Pituitary Neoplasms/complications
Thyrotropin/secretion
[Mh] MeSH terms secundary: Adenoma/diagnosis
Adenoma/secretion
Adenoma/surgery
Adult
Female
Humans
Infertility, Male/therapy
Male
Pituitary Neoplasms/diagnosis
Pituitary Neoplasms/secretion
Pituitary Neoplasms/surgery
Pregnancy
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:9002-71-5 (Thyrotropin)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009546

  3 / 16515 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29520804
[Au] Autor:Yu Y; Yu N; Lu G; Li T; Zhang Y; Zhang J; Gao Y; Gao Y; Guo X
[Ad] Address:Department of Endocrinology, Peking University First Hospital, Beijing, 100034, China.
[Ti] Title:Hashimoto's thyroiditis with elevated serum IgG4 concentrations is not equivalent to IgG4 Hashimoto's thyroiditis.
[So] Source:Clin Endocrinol (Oxf);, 2018 Mar 09.
[Is] ISSN:1365-2265
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Hashimoto's thyroiditis (HT) with serum IgG4 concentrations greater than 135 mg/dl can be diagnosed as elevated serum IgG4 HT. HT can also be classified into IgG4 HT and non-IgG4 HT based on an immunohistochemistry analysis of IgG4. The aim of our study was to determine the relationship between elevated serum IgG4 HT and IgG4 HT. METHOD: 93 HT patients with both thyroid tissues and serum samples stored before pathological examination were collected. The serum levels of IgG, IgG4, TgAb IgG, TgAb IgG4, TPOAb IgG, and TPOAb IgG4 were measured by ELISAs. The expression levels of IgG4, IgG and TGF-ß1 in thyroid tissues were detected by immunohistochemistry. RESULTS: HT patients were divided into two groups: elevated serum IgG4 HT (n = 12) and non-elevated serum IgG4 HT (n = 81). Hypothyroidism was found in 5/12 cases (41.7%) in the elevated serum IgG4 HT group and 10/81 cases (12.3%) in the non-elevated serum IgG4 HT group (P = 0.023). Serologically, there were no significant differences in the levels of TgAb IgG, TPOAb IgG, TgAb IgG4, and TPOAb IgG4 between the two groups, and the expression of TGF-ß1 in thyroid tissues was not significantly different between the groups. Most importantly, the frequency of patients who satisfied the criteria for IgG4 HT diagnosis was comparable (25% vs. 20.9%, P = 0.756). CONCLUSIONS: The measurement of serum IgG4 allows the identification of HT patients closely associated with hypothyroidism. However, our study demonstrated that elevated serum IgG4 HT is not equivalent to IgG4 HT. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1111/cen.13596

  4 / 16515 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29519715
[Au] Autor:Johnson C; Jazaeri AA
[Ad] Address:Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: cynae.johnson@mdanderson.org.
[Ti] Title:Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes.
[So] Source:Clin Ther;, 2018 Mar 05.
[Is] ISSN:1879-114X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Use of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1 have led to improved survival outcomes for advanced solid-tumor malignancies. This report helps the reader gain a better understanding of adverse events in patients with ovarian cancer on checkpoint inhibitor therapy. We describe 3 hypothetical case vignettes of patients with gynecologic cancer on checkpoint inhibitor immunotherapy and discuss common immune-related adverse events. The typical presentation and onset of immune-related events are different from those associated with conventional chemotherapy. This report highlights the importance of early recognition and management of these events.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  5 / 16515 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29515055
[Au] Autor:Hanew K; Tanaka T; Horikawa R; Hasegawa T; Yokoya S
[Ad] Address:Growth Hormone Therapy Research Committee, Foundation for Growth Science, Tokyo, Japan.
[Ti] Title:Prevalence of diverse complications and its association with karyotypes in Japanese adult women with Turner syndrome-a questionnaire survey by the Foundation for Growth Science.
[So] Source:Endocr J;, 2018 Mar 07.
[Is] ISSN:1348-4540
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:The reported prevalence of complications in Turner Syndrome (TS) was highly variable because of the rarity and the limited numbers analyzed. Again, possible presence of other complications that are not described as specific for TS, is also speculated. To resolve these issues, a questionnaire survey was conducted in hGH treated 492 patients with adult TS (17-42 years). The possible association with these complications and karyotypes were also analyzed. The complications and their prevalence were as follows: chronic thyroiditis (25.2%), inflammatory bowel disease (1.8%), congenital cardiovascular anomaly (11.8%), urinary tract malformation (11.8%), low bone mineral density (BMD) (42.9%), scoliosis (8.4%), hearing loss (6.2%), epilepsy (2.8%) and schizophrenia (0.9%). The majority of prevalence of these diseases in TS was higher than in the general population. In distribution, the most frequent karyotype was 45,X monosomy (28.9%), followed by 45,X/46,X,Xi (16.9%), 46,X,Xi (9.1%), and 45,X/46,XX (6.3%), while other mosaic 45,X was noted in 29.9%. Regarding the karyotype, cardiovascular anomaly was more frequent in the 45,X group and less in the 46,X,Xi group. Urinary tract malformation and epilepsy were frequently associated with the chromosome 45,X. The prevalence of low BMD was noticed more in the chromosome 46,X,Xi and 45,X/46,X,Xi, and less in other mosaic 45,X. In conclusion, the more exact prevalence of diverse complications was clarified and it exceeded the prevalence of the majority of complications in general population. As novel findings, it was observed that the prevalence of epilepsy was significantly high, and epilepsy and low BMD were frequently associated with the specific karyotypes.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1507/endocrj.EJ17-0401

  6 / 16515 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29279030
[Au] Autor:Arellano K; Mosley JC; Moore DC
[Ad] Address:1 Department of Pharmacy, Southeast Health, Cape Girardeau, MO, USA.
[Ti] Title:Case Report of Ipilimumab-Induced Diffuse, Nonnecrotizing Granulomatous Lymphadenitis and Granulomatous Vasculitis.
[So] Source:J Pharm Pract;31(2):227-229, 2018 Apr.
[Is] ISSN:1531-1937
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Ipilimumab is indicated for the treatment of melanoma in both the metastatic and adjuvant setting. Ipilimumab inhibits cytotoxic T-lymphocyte antigen 4, leading to the augmentation of T-cell activity and an antitumor immune system response. The side effect profile of ipilimumab consists of autoimmune-like events such as dermatitis, colitis, and thyroiditis. These immune-related adverse events can be serious, often resulting in the need for systemic immunosuppression with corticosteroids. We present a case of diffuse, nonnecrotizing granulomatous lymphadenitis and granulomatous vasculitis in a heavily pretreated patient with metastatic melanoma. After completion of 4 cycles of ipilimumab for the treatment of metastatic melanoma, our patient complained of increasing fatigue, drenching night sweats, and chills. Imaging revealed diffuse adenopathy involving several lymph nodes. Biopsy was positive for nonnecrotizing granulomatous lymphadenitis and granulomatous vasculitis. High-dose prednisone was initiated and tapered gradually over 6 weeks, resulting in complete resolution of the granulomatous disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.1177/0897190017699762

  7 / 16515 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29512805
[Au] Autor:Bani MA; Zehani A; Chelly I; Khadhar A; Haouet S; Kchir N
[Ti] Title:Warthin-like papillary carcinoma associated with Hashimoto thyroiditis and systemic granulomatosis: a case report.
[So] Source:Tunis Med;95(6):447-448, 2017 Jun.
[Is] ISSN:0041-4131
[Cp] Country of publication:Tunisia
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review

  8 / 16515 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29510406
[Au] Autor:Li L; Ding X; Wang X; Yao Q; Shao X; An X; Yan N; Jiang Y; Wang W; Shi L; Qin Q; Song R; Zhang JA; Sun P
[Ad] Address:Department of Endocrinology, Jinshan Hospital of Fudan University, Shanghai, China.
[Ti] Title:Polymorphisms of IKZF3 Gene and Autoimmune Thyroid Diseases: Associated with Graves' Disease but Not with Hashimoto's Thyroiditis.
[So] Source:Cell Physiol Biochem;45(5):1787-1796, 2018 Feb 28.
[Is] ISSN:1421-9778
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:BACKGROUND/AIMS: The IKZF3 gene encodes a zinc-finger protein that plays an important role in the proliferation and differentiation of B lymphocytes. Autoimmune thyroid diseases (AITDs), mainly include Graves' disease (GD) and Hashimoto's thyroiditis (HT), are probably caused by the aberrant proliferation of B cells. The objective of this study was to explore the association between IKZF3 polymorphisms and AITDs. METHODS: We examined 915 AITD patients (604 GD and 311 HT) and 814 healthy controls. IKZF3 variants (rs2941522, rs907091, rs1453559, rs12150079 and rs2872507) were tested by PCR-ligase detection reaction. RESULTS: It was manifested that that the minor alleles of the five loci increased susceptibility to GD (p<0.05 for rs2941522, and p<0.01 for rs907091, rs1453559, rs12150079 and rs2872507) but in HT patients, these loci showed no significant difference compared with controls. Similarly, the genotype distributions of GD patients manifested obvious differences in all these loci compared with the control group, whereas no statistical differences were observed between HT patients and controls. Furthermore, bioinformatics tools were used to analyze rs1453559, rs12150079 and rs907091. These variants were believed to be the transcription regulator. CONCLUSION: It is the first time we reported the association between the IKZF3 polymorphisms and GD, indicating that IKZF3 gene tends to bean important risk factor for the development of GD.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:Publisher
[do] DOI:10.1159/000487870

  9 / 16515 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29444549
[Au] Autor:Glick R; Chang P; Michail P; Serpell JW; Grodski S; Lee JC
[Ad] Address:Monash University Endocrine Surgery Unit, The Alfred Hospital, Melbourne, Victoria, Australia.
[Ti] Title:Body weight change is unpredictable after total thyroidectomy.
[So] Source:ANZ J Surg;88(3):162-166, 2018 Mar.
[Is] ISSN:1445-2197
[Cp] Country of publication:Australia
[La] Language:eng
[Ab] Abstract:BACKGROUND: There is a common perception that total thyroidectomy causes weight gain beyond expected age-related changes, even when thyroid replacement therapy induces a euthyroid state. The aim of this study was to determine whether patients who underwent total thyroidectomy for a wide spectrum of conditions experienced weight gain following surgery. METHODS: We retrospectively studied 107 consecutive total thyroidectomy patients treated between January 2013 and June 2014. Medical records were reviewed to determine underlying pathology, thyroid status, use of antithyroid drugs and preoperative weight. Follow-up data were obtained from 79 patients at least 10 months post-operatively to determine current weight, the type of clinician managing thyroid replacement therapy and patient satisfaction with post-thyroidectomy management. RESULTS: The cohort was 73% female, with a mean age of 55.8 ± 15.7 years and a mean preoperative weight of 78.8 ± 17.5 kg. Commonest pathologies were multinodular goitre, Graves' disease, thyroid cancer and Hashimoto's thyroiditis. Preoperatively, 63.2% of patients were hyperthyroid. Mean weight change at follow-up was a non-significant increase of 0.06 ± 6.9 kg (P = 0.094). Weight change was not significant regardless of preoperative thyroid function status. This study did not demonstrate any significant differences in clinical characteristics (including post-operative thyroid-stimulating hormone) between the group with >2% weight gain and those who did not. CONCLUSIONS: This study did not reveal significant weight gain following thyroidectomy for a wide spectrum of pathologies. Specifically, preoperative hyperthyroidism, female gender and use of antithyroid medications do not predict weight gain after thyroid surgery.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review
[do] DOI:10.1111/ans.14421

  10 / 16515 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29372654
[Au] Autor:Stozek K; Bossowski A; Ziora K; Bossowska A; Mrugacz M; Noczynska A; Walczak M; Petriczko E; Pyrzak B; Kucharska A; Szalecki M; Diana T; Kahaly GJ
[Ad] Address:a Department of Pediatric Endocrinology, Diabetology with Cardiology Division , Medical University of Bialystok , Bialystok , Poland.
[Ti] Title:Functional TSH receptor antibodies in children with autoimmune thyroid diseases.
[So] Source:Autoimmunity;51(2):62-68, 2018 Mar.
[Is] ISSN:1607-842X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: The diagnostic value of the level of TSH receptor antibodies (TSHR-Ab) in the population of children with autoimmune thyroid diseases (AITDs) is still unknown. The aim of this cross-sectional study was to investigate the prevalence of TSHR-Ab in a paediatric cohort with AITD and healthy controls. MATERIALS AND METHODS: A total of 240 serum samples were obtained from 205 patients with AITD, type 1 diabetes (T1D), juvenile arthritis (JA), and healthy controls (C). TSHR stimulating (TSI) and -blocking (TBI) immunoglobulins were measured in cell-based bioassays using CHO cells expressing a chimeric TSHR and a c-AMP response-element-dependent luciferase. TSI was reported as percentage of specimen-to-reference ratio (cutoff 140SRR%). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine TSH alone (40% inhibition). RESULTS: C as well as children with JA and T1D were both TSI and TBI negative. In contrast, children with Graves' disease (GD) were positive for TSI in 47/53 samples (88.7%) while those with thyroidal and orbital GD showed TSI positivity in 95.8% (23/24 samples). Serum TSI levels were SRR% 320 ± 157 and 417 ± 135 in GD and GD + orbitopathy, respectively (p = .02). Children with Hashimoto's thyroiditis (HT) were TSI positive in 4/83 (4.8%) samples, including two with orbital involvement. TSI levels were increased in HT children with vs. those without eye disease (SRR% 177 vs. 51, p < .01). In comparison, TBI were negative in all tested samples of children with GD but positive in one HT sample. CONCLUSIONS: In conclusion, TSI is prevalent in children with GD while the highest serum TSI levels were noted in children with AITD and orbitopathy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review
[do] DOI:10.1080/08916934.2018.1431776


page 1 of 1652 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information